From HCV testing to treatment in social relief centres in Amsterdam
Eberhard Schatz, Amsterdam, The Netherlands

**Aim:**
A model of care, ‘proof-of-concept’ study by De Regenboog, the Mainline Foundation and the Public Health Service of Amsterdam to inform the effectiveness of providing HCV screening and linkage to care (LTC) in social relief shelters and walk-in centres in Amsterdam.

**Why is the model ‘proof-of-concept’ needed?**

**HCV infection** in The Netherlands primarily occurs in high-risk groups and key target groups have been identified and prioritised for treatment:
- PWID
- HIV+
- Haemophilia patients born before 1992
- Migrants from endemic countries
- Prisoners
- High risk HIV-negative MSM
- People with a high risk for HCV infection (e.g. unsafe IDU, high-risk MSM, unsafe tattoos) who do not receive medical care or methadone treatment are often lost to mainstream healthcare

**2014 survey:**

- 86 clients of walk-in centres in Amsterdam who were ever drug-users
- 91% had risk of HCV infection
- Only 22% tested for HCV
- Of the 3% who were HCV+0 tested for HCV

**What is the model and how does it work?**

This ‘proof-of-concept’ study is a collaboration between community and public organisations:

- Public Health Service of Amsterdam (GGD Amsterdam)
- Nurses and social relief centre personnel
- Treating physician at referral hospital

**Interventions used to enhance HCV testing, LTC and treatment uptake**
- Nurse-led rapid HCV antibody testing (OraQuick® test) at low threshold settings (social relief centres)
- Onsite HCV education for support staff and clients
- Off-site HCV RNA testing with facilitated referral and non-invasive liver disease assessment using transient elastography

**Outcomes and future directions**

- 233 of ~500 clients completed risk checklist
- 90% self-reported risk of HCV
- 225 screened for HCV Ab
- 9.8% anti-HCV Ab+

**HCV cascade of care**

- 50% drop-out between HCV Ab & HCV RNA testing
- 50% drop-out between referral and treatment

**Reasons for high drop-out**
- Patient not presenting for referral/treatment
- Patient not motivated to undergo treatment
- Patient not referred
- Patient does not want venous blood draw

**Lessons learnt**
- Provide targeted information to clients & staff
- Appoint ‘hepatitis ambassadors’
- Monitor and supervise HCV+ patients
- Onsite HCV RNA testing after a positive HCV Ab result is recommended
- Proof-of-concept onsite HCV Ab & RNA testing with finger-stick blood sample

This research confirms that clients in social relief centres form a risk group for HCV who should be tracked and prioritised for HCV screening and LTC in accordance with the advice of the Health Council.

The prevalence of HCV and risk of HCV infection are high amongst clients who use social relief centres in Amsterdam, confirming that an onsite ‘test-and-treat’ approach in these environments will be the optimal model of care. High drop-out rates between screening, referral and treatment suggest that extra attention is required to ensure clients receive treatment.

---

**Date of preparation:** September 2019. HCV/HQ/19-02/1239y © Gilead Sciences Europe Ltd

---

6. Eberhard Schatz, Amsterdam, The Netherlands

---

This initiative has received funding from Gilead Sciences. This meeting has been organised and funded by Gilead Sciences Europe Ltd.